LabCorp

291 articles about LabCorp

• LabCorp Celebrates 50 Years of Improving Health, Improving Lives

  10/15/2019

  LabCorp® announced that it will mark its 50th anniversary at a celebration Oct. 15 in Burlington, North Carolina, where the company has been headquartered since its founding. Dr. James B. Powell and his brothers, Dr. Thomas Edward Powell III and John Powell, founded LabCorp’s predecessor company, Biomedical Laboratories, in the former Alamance General Hospital building and tested the company’s first specimens on Oct.

• Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021 - Oct. 14, 2019

  10/14/2019

  LabCorp® announced that its Zero Coupon Convertible Subordinated Notes due 2021 may be converted as set forth below.

• LabCorp Announces New Leadership Roles for Its Two Business Segments and Selects New Chief Human Resources Officer

  10/3/2019

  LabCorp® announced that John Ratliff, currently CEO of Covance, will become CEO of LabCorp Diagnostics, and Dr. Paul Kirchgraber, currently senior vice president and head of Covance’s clinical trial testing solutions, will succeed Ratliff as CEO of Covance.

• LabCorp Publishes Largest Study to Date on Prenatal Cell-Free DNA Screenings in Multifetal Pregnancies

  9/30/2019

  Study of nearly 30,000 cases finds that non-invasive cfDNA screening for fetal aneuploidy in pregnancies with twins, triplets, and higher-order multiples meets or exceeds performance of singleton pregnancy screening

• LabCorp to Announce Third Quarter Financial Results on October 24, 2019

  9/24/2019

  Interested parties can access the conference call by dialing 844-634-1444 within the U.S. and Canada, or 615-247-0253 internationally, using the passcode 2682119.

• LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 To Accrue Contingent Interest from September 11, 2019 to March 10, 2020

  9/11/2019

  LabCorp® announced that for the period of Sept. 11, 2019 to March 10, 2020, its Zero Coupon Convertible Subordinated Notes due 2021 will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended Sept. 6, 2018, in addition to the continued accrual of the original issue discount.

• Covance Unveils New R&D Center in Shanghai

  9/10/2019

  Inauguration Ceremony Highlights World-Class, Comprehensive Drug Development Capabilities and More Than Two Decades of Growth in China

• Covance Launches Laboratory Data Management Functional Service Provider for Pharmaceutical and Biotechnology Customers

  8/29/2019

  Program Expands the Company’s Growing and Unique FSPx Capabilities

• LabCorp is Scheduled to Present at the Morgan Stanley Global Healthcare Conference - Aug. 29, 2019

  8/29/2019

  LabCorp® announced it will participate at the Morgan Stanley Global Healthcare Conference.

• LabCorp Announces 2019 Second Quarter Results and Updates 2019 Guidance

  7/25/2019

  LabCorp® announced results for the second quarter ended June 30, 2019, and updated 2019 guidance.

• LabCorp Expands Consumer-Initiated Test Offering

  7/22/2019

  Pixel by LabCorp Now Available with Phlebotomy Collection Through LabCorp’s Nationwide Patient Service Center Network

• Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021 - July 1, 2019

  7/1/2019

  LabCorp® announced that its Zero Coupon Convertible Subordinated Notes due 2021 may be converted as set forth below.

• LabCorp to Announce Second Quarter Financial Results on July 25, 2019

  6/25/2019

  The webcast will be archived and accessible through July 24, 2020.

• LabCorp and Mount Sinai Health System Collaborate to Establish Digital and AI-Enabled Pathology Center of Excellence

  6/18/2019

  Philips IntelliSite Pathology Solution will be deployed across the Mount Sinai Health System to support greater efficiency and help improve patient care

• LabCorp and QIAGEN Announce New therascreen PIK3CA Mutation Analysis Companion Diagnostic for Metastatic Breast Cancer

  6/7/2019

  LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced a new companion diagnostic called therascreen® PIK3CA PCR mutation analysis, which is now available through LabCorp and its Integrated Oncology specialty laboratory.

• LabCorp Announces New Leadership Roles

  6/5/2019

  David P. King, current chairman, president and CEO of LabCorp, to become executive chairman of the board of directors effective Nov. 1, retiring Oct. 31 as president and CEO

• LabCorp Announces New Term Loan Facility

  6/3/2019

  On June 3, 2019, LabCorp® entered into a new Term Loan Credit Agreement, which provides for a two-year term loan credit facility in the principal amount of $850 million.

• LabCorp and Envigo Complete Innovative Transactions

  6/3/2019

  LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, and Envigo, a leading provider of research models and services, today announced that they have completed previously announced transactions that will strengthen and enhance the way their respective businesses support research in the biopharmaceutical and life sciences industries.

• LabCorp Announces Availability of New QIAGEN therascreen FGFR mutation analysis companion diagnostic for Bladder Cancer

  5/10/2019

  LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced the availability of a newly-approved companion diagnostic by the U.S. Food and Drug Administration (FDA), the therascreen® FGFR mutation assay by RGQ RT-PCR,

• KIYATEC Announces $3 Million Initial Closing of Series B2 Preferred Stock Financing and New Investor LabCorp

  5/1/2019

  The round was led by VentureSouth and included LabCorp®